DRDO COVID-19 Drug 2-DG To Be Manufactured, Marketed By Mankind Pharma As Firm Receives Approval

<p><strong>New Delhi: </strong>The Defence Research and Development Organisation (DRDO) has given licence to drug firm Mankind Pharma to manufacture and market oral 2-deoxy-D-glucose (2-DG), which is used for the treatment of Covid-19.</p> <p>Mankind Pharma in a statement said 2-DG was developed by the Defence Research and Development Establishment (DRDE), Gwalior.</p> <p>The drug firm added the clinical trials were conducted by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in association with Dr Reddy's Laboratories.</p> <p><strong>READ</strong>: <span style="color: #e03e2d;"><strong><a style="color: #e03e2d;" href="https://ift.tt/3yse8H0 - GSK Get DCGI Nod For Conducting Phase 3 Trial Of Their COVID Vaccine In India; All You Need To Know</a></strong></span></p> <p>Mankind Pharma will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh.</p> <p>The office of the Drugs Controller General of India (DCGI) had on May 1 permitted the emergency use of 2-DG as an adjunct treatment for moderate to severe COVID-19 patients, PTI reported Mankind Pharma as saying.</p> <p>The company said this drug is found to help the hospitalised coronavirus patients recover faster, adding it is also known to reduce the supplemental oxygen dependency among the Covid-19 patients.</p> <p><strong>ALSO READ</strong>: <span style="color: #e03e2d;"><strong><a style="color: #e03e2d;" href="https://ift.tt/3dOx5Mg Covid, Oxford Scientists Target HIV; Human Trials Of Vaccine Begins</a></strong></span></p> <p>Mankind Pharma further stated, &ldquo;our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic&rdquo;.</p>

from covid-19 https://ift.tt/3dXcF3t